The AI Impact with Generate:Biomedicines' Mike Nally
Source: Bioprocess Online
Few drug discovery and development concepts are as hyped, and as such, draw as much polarity from drug developers, as machine learning and artificial intelligence. One company on the bullish end of the spectrum is Flagship Pioneering's Generate: Biomedicines, which bills itself at the "intersection of machine learning, biological engineering, and medicine."
access the Video!
Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue.
X
Enter your credentials below to log in. Not yet a member of Biosimilar Development? Subscribe today.
Subscribe to Biosimilar Development
X
Subscribe to Biosimilar Development
This website uses cookies to ensure you get the best experience on our website. Learn more